A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in Patients with Chronic Lymphocytic Leukemia.

Drug Category : Array
Conference Category : Array
Lead Author : Mahadevan D, et al.
Published Date : 08/12/2015
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/TGR-Gazyva%20ASH%202015%20FINAL.PDF
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
astra-migrate-meta-layouts : set
stick-header-meta : default
Scroll to Top